NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
“AML Express enhances our hematologic portfolio by addressing the clinical need for faster testing that informs critical treatment decisions,” said Chris Smith, CEO of NeoGenomics. “This new test offers physicians a more efficient solution that delivers patient-specific insights to guide precise treatment strategies.”
AML accounts for about one out of three leukemias in adults. It is an aggressive disease that often develops and progresses rapidly over a few weeks, making access to timely and accurate diagnostic and prognostic information critical for patient care. With a turnaround time of just three to four days, AML Express delivers a time- and cost-effective alternative to traditional single-gene testing methods.
The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. AML Express simplifies the decision-making process for clinicians, facilitates patient enrollment in clinical trials, and supports the development of personalized treatment strategies.
NEO shares gained four cents to $13.82.
